Nitrogen-containing heteroaryl compounds and methods of user thereof

1. A compound represented by formula IA:

wherein

q is zero or one;

R 1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, halo, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, and —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl or, when X is —NR 7 —, then R 7 and R 6 , together with the nitrogen atom to which they are bound, can be joined to form a heterocyclic or substituted heterocyclic group;

R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, —S(O) n —N(R 6 )—R 6 where n is 0, 1, or 2, —NR 6 C(O)NR 6 R 6 , —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, each R 6 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic provided that when X is —SO— or —SO 2 —, then R 6 is not hydrogen, and R 7 is selected from the group consisting of hydrogen, alkyl, aryl, or R 2 , R 3 together with the carbon atom pendent thereto, form an aryl substituted aryl, heteroaryl, or substituted heteroaryl;

R 4 and R 5 are independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl and —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl or, when X is —NR 7 —, then R 7 and R 6 , together with the nitrogen atom to which they are bound, can be joined to form a heterocyclic or substituted heterocyclic group;

R is selected from the group consisting of hydrogen, deuterium, alkyl, and aryl;

R′ is selected from the group consisting of deuterium, alkyl, substituted alkyl, and substituted amino; alternatively, R and R′ and the carbon pendent thereto can be joined to form cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group;

R″ is selected from the group consisting of hydrogen and alkyl or R′, R″, and the carbon atom and the nitrogen atom respectively pendent thereto can be joined to form a heterocyclic or substituted heterocyclic group;

R′″ is selected from the group consisting of hydroxy, thiol, alkoxy, substituted alkoxy, acyloxy, cycloalkoxy, substituted cycloalkoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, aryl, —S(O) n —R 10 wherein R 10 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl and n is zero, one or two;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

2. A compound as in claim 1 , wherein R 1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, halo, alkoxy, substituted alkoxy, aryloxy, substituted aryloxy, substituted aryl, aminoacyl, aryl, —N(R 6 )(R 7 ), heteroaryl, heteroaryloxy, —S(O) n -aryl, —S(O) n -substituted aryl, —S(O) n -heteroaryl, and —S(O) n -substituted heteroaryl, where n is zero, one or two, and where R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl or R 7 and R 6 , together with the nitrogen atom to which they are bound, can be joined to form a heterocyclic or substituted heterocyclic group.

3. A compound as in claim 2 , wherein R 1 is selected from the group consisting of:

2,6-dimethylphenoxy;

3,4-difluorophenoxy;

3,5-difluorophenoxy;

3-chloro-4-fluorophenoxy;

3-methoxy-4-fluorophenoxy;

3-methoxy-5-fluorophenoxy;

4-(methylsulfonamido)phenoxy;

4-(phenylsulfonamido)phenoxy;

4-CF 3 —O-phenoxy;

4-CF 3 -phenoxy;

4-chlorophenoxy;

4-fluorophenoxy;

4-(4-fluorophenoxy)phenoxy;

4-methoxyphenoxy;

4-nitrophenoxy;

benzyloxy;

bromo;

butoxy;

CF 3 ;

chloro;

fluoro;

hydrogen;

iodo;

isopropoxy;

methyl;

phenoxy;

phenyl;

phenylsulfanyl;

phenylsulfinyl;

phenylsulfonyl;

pyridin-1-ylsulfanyl;

pyridin-3-yloxy; and

pyridin-4-ylsulfanyl.

4. A compound as in claim 1 , wherein R 2 is selected from the group consisting of —N(R 6 )(R 7 ), aryloxy, substituted aryloxy, alkoxy, substituted alkoxy, halo, hydrogen, alkyl, substituted alkyl, aryl, —S(O) n -aryl, —S(O) n -substituted aryl, —S(O) n -cycloalkyl, —S(O) n -heteroaryl, where n is zero, one or two, —NR 6 C(O)NR 6 R 6 , heteroaryloxy, and cycloalkyloxy.

5. A compound as in claim 4 , wherein R 2 is selected from the group consisting of:

2,6-dimethylphenoxy;

3,4-difluorophenoxy;

3,5-difluorophenoxy;

3-chloro-4-fluorophenoxy;

3-methoxy-4-fluorophenoxy;

3-methoxy-5-fluorophenoxy;

4-(methylsulfonamido)phenoxy;

4-(phenylsulfonamido)phenoxy;

4-CF 3 —O-phenoxy;

4-CF 3 -phenoxy;

4-chlorophenoxy;

4-fluorophenoxy;

4-(4-fluorophenoxy)phenoxy;

4-methoxyphenoxy;

4-nitrophenoxy;

benzyloxy;

bromo;

butoxy;

CF 3 ;

chloro;

cyclohexyloxy;

cyclohexylsulfanyl;

cyclohexylsulfonyl;

fluoro;

hydrogen;

iodo;

isopropoxy;

methyl;

phenoxy;

phenyl;

phenylsulfanyl;

phenylsulfinyl;

phenylsulfonyl;

phenylurea;

pyridin-1-ylsulfanyl;

pyridin-3-yloxy; and

pyridin-4-ylsulfanyl.

6. A compound as in claim 1 , wherein R 3 is selected from the group consisting of substituted aryloxy, substituted alkoxy, alkoxy, substituted alkyl, alkyl, amino, cycloalkyloxy, hydrogen, halo, aryl, —S(O) n -aryl, —S(O) n -substituted aryl, —S(O) n -heteroaryl, —S(O) n -substituted heteroaryl, where n is zero, one or two, —NR 6 C(O)NR 6 R 6 , and heteroaryloxy.

7. A compound as in claim 6 , wherein R 3 is selected from the group consisting of:

amino;

(4-methyl)phenylsulfonylaminophenoxy;

3,4-difluorophenoxy;

3,5-difluorophenoxy;

3-fluoro-5-methoxy-phenoxy;

3-chloro-4-fluorophenoxy

4-CF 3 —O-phenoxy;

4-CF 3 -phenoxy;

4-chlorophenoxy;

4fluorophenoxy;

4-(4-fluorophenoxy)phenoxy;

4-methoxyphenoxy;

benzyloxy;

bromo;

butoxy;

CF 3 ;

chloro;

cyclohexyloxy;

hydrogen;

iodo;

isopropoxy;

phenoxy;

phenyl;

phenylsulfanyl;

phenylsulfonyl;

phenylsulfinyl;

phenylurea;

pyridin-1-ylsulfanyl;

pyridin-3-yloxy; and

pyridin-4-ylsulfanyl.

8. A compound as in claim 1 , wherein R 2 and R 3 , together with the carbon atom pendent thereto, join to form an aryl group.

9. A compound as in claim 8 , wherein said aryl group is phenyl.

10. A compound as in claim 1 , wherein R 4 is selected from the group consisting of halo, hydrogen, substituted alkyl, aryl, and —S(O) n -substituted aryl where n is zero, one or two.

11. A compound as in claim 10 , wherein R 4 is selected from the group consisting of:

4-chlorophenyl sulfanyl;

chloro;

hydrogen;

methoxymethyl; and

phenyl.

12. A compound as in claim 1 , wherein R 5 is hydrogen or aryl.

13. A compound as in claim 12 , wherein R 5 phenyl.

14. A compound as in claim 1 , wherein R is selected from the group consisting of phenyl, hydrogen, deuterium and methyl.

15. A compound as in claim 1 , wherein R′ is selected from the group consisting of deuterium, alkyl, substituted alkyl, and substituted amino.

16. A compound of claim 15 , wherein R′ is selected from the group consisting of:

4-aminobutyl;

4-hydroxybenzyl;

benzyl;

carboxylmethyl;

deuterium;

hydroxymethyl;

imidazol-4-ylmethyl;

isopropyl;

methyl; and

propyl.

17. A compound as in claim 1 , wherein R, R′ and the carbon atom pendent thereto join to form a cycloalkyl.

18. A compound as in claim 17 , wherein said cycloalkyl is cyclopropyl.

19. A compound as in claim 1 , wherein R″ is hydrogen.

20. A compound as in claim 1 , wherein R′, R″ and the carbon atom and nitrogen atom respectively pendent thereto join to form a heterocyclic group.

21. A compound as in claim 20 , wherein said heterocyclic group is pyrrolidinyl.

22. A compound as in claim 1 , wherein R′″ is selected from the group consisting of hydroxy, alkoxy, substituted alkoxy, thiol, acyloxy and aryl.

23. A compound as in claim 22 , wherein R′″ is selected from the group consisting of:

hydroxy;

benzyloxy;

ethoxy;

methoxy;

methylcarbonyloxy; and

phenyl.

24. A compound as in claim 1 , wherein said compound is represented by formula IIA:

wherein:

q is zero or one;

R 1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, halo, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, and —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl;

R 4 and R 5 are independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl and —XR 6 where X is oxygen, —S(O) n — or —NR 7 — where n is zero, one or two, R 6 selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R 7 is hydrogen, alkyl or aryl;

R is selected from the group consisting of hydrogen and methyl;

R′ is selected from the group consisting of alkyl and substituted alkyl; or R and R′ may be joined to form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic; and

R″ is selected from the group consisting of hydrogen and alkyl or R″ together with R′ and the nitrogen pendent thereto forms a heterocyclic or substituted heterocyclic group;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

25. A compound selected from the group consisting of:

2-(S)-{[7-(4-Chloro-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-propionic acid;

2-(S)-{[6-(4-Chloro-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-propionic acid;

2-{[7-(3,4-Difluoro-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-propionic acid;

2-(S)-[(4-Hydroxy-7-phenylsulfanyl-isoquinoline-3-carbonyl)-amino]-propionic acid;

2-(R)-[(4-Hydroxy-7-phenylsulfanyl-isoquinoline-3-carbonyl)-amino]-propionic acid;

2-(R)-[(4-Hydroxy-7-phenoxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

2-(S)-{[4-Hydroxy-7-(4-methoxy-phenoxy)-isoquinoline-3-carbonyl]-amino}-propionic acid;

2-(S)-[(7-Benzenesulfonyl-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(R)-2-[(4-Hydroxy-1-methoxymethyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-propionic acid; (

S)-2-[(4-Hydroxy-1-methoxymethyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(S)-2-[(4-Mercapto-7-phenoxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(S)-2-{[1-(4-Chloro-phenylsulfanyl)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-propionic acid;

(R)-2-{[1-(4-Chloro-phenylsulfanyl)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-propionic acid;

(S)-2-[(6-Benzyloxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-hydroxy -propionic acid;

(S)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-hydroxy -propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-hydroxy-propionic acid;

(S)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-hydroxy-propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-hydroxy-propionic acid;

(S)-2-[(1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-hydroxy-propionic acid;

2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-2-methyl-propionic acid;

2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-2-methyl-propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-(1H-imidazol-4-yl)-propionic acid (trifluoro-acetic acid salt);

(S)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-(1H-imidazol-4-yl)-propionic acid (trifluoro-acetic acid salt);

(R)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-methyl-butyric acid;

(S)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-methyl-butyric acid;

(R)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-methyl-butyric acid;

(S)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-methyl-butyric acid;

(R)-2-[(1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-methyl-butyric acid;

(S)-2-[(1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-methyl-butyric acid;

(S)-2-[(6-Benzyloxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-methyl-butyric acid;

(R)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-phenyl-propionic acid;

(S)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-phenyl-propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-phenyl-propionic acid;

(S)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-phenyl-propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-phenyl-propionic acid;

(S)-2-[(1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-phenyl-propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid;

(S)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid;

(S)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid;

(S)-2-[(1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-pentanoic acid;

(S)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-pentanoic acid;

(R)-1-(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-pyrrolidine-2-carboxylic acid;

(S)-1-(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-pyrrolidine-2-carboxylic acid;

(R)-1-(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-pyrrolidine-2-carboxylic acid;

(S)-1-(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-pyrrolidine-2-carboxylic acid;

(R)-6-Amino-2-[(1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-hexanoic acid (trifluoro-acetic acid salt);

(S)-6-Amino-2-[(1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-hexanoic acid (trifluoro-acetic acid salt);

(R)-6-Amino-2-[(1-chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-hexanoic acid trifluoroacetic acid salt;

(S)-6-Amino-2-[(1-chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-hexanoic acid (trifluoro-acetic acid salt);

(R)-6-Amino-2-[(1-chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-hexanoic acid trifluoroacetic acid salt;

(S)-6-Amino-2-[(1-chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-hexanoic acid (trifluoro-acetic acid salt);

(R)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-succinic acid;

(S)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-succinic acid;

(R)-2-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-succinic acid;

(S)-2-[-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-succinic acid;

(R)-2-[(1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-succinic acid;

1-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-cyclopropanecarboxylic acid;

1-[(1-Chloro-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-cyclopropanecarboxylic acid;

Dideutero-[(1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid;

(R)-2-[(6-Benzyloxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(S)2-[(7-Benzyloxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(R)-2-[(7-Benzyloxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(S)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(R)-2-[(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(S)-2-[(6-Isopropoxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(R)-2-[6-Isopropoxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(S)-2-[(7-Isopropoxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

(R)-2-[(7-Isopropoxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]propionic acid;

(S)-2-{[7-(3-Fluoro-5-methoxy-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-propionic acid;

2-(S)-[(7-Cyclohexyloxy-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

2-(S)-{[7-(4-Fluoro-phenoxy)-4-hydroxy-1-methyl-isoquinoline-3-carbonyl]-amino}-propionic acid;

2-(S)-{[7-(4-Fluoro-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-propionic acid;

2-(S)-[(4-Hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-propionic acid;

2-(S)-[(4-Hydroxy-1-methyl-7-phenylsulfanyl-isoquinoline-3-carbonyl)-amino]-propionic acid; and

2-(S)-{[4-Hydroxy-7-(4-trifluoromethyl-phenoxy)-isoquinoline-3-carbonyl]-amino}-propionic acid;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

26. A compound represented by formula:

wherein:

R 1 is selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, and —XR 6 where X is S and R 6 is aryl or substituted aryl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, and —XR 6 where X is oxygen, or —S(O) n where n is zero or two, each R 6 is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, and heterocyclic;

R is selected from hydrogen, alkyl, and deuterium;

R′ is selected from deuterium, alkyl, and substituted alkyl, or alternatively, R and R′ and the carbon pendent thereto can be joined to form a cycloalkyl; and

R″ is hydrogen or alkyl, or R″ together with R′ and the nitrogen pendent thereto can be joined to form a heterocyclic group;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

27. A compound as in claim 26 , wherein R 1 is selected from the group consisting of hydrogen, chloro, methyl, methoxymethyl, and 4-chlorophenylsulfanyl.

28. A compound as in claim 27 , wherein R 1 is hydrogen, methyl, or methoxymethyl.

29. A compound as in claim 26 , wherein R 2 and R 3 are independently selected from the group consisting of hydrogen, benzyloxy, isopropoxy, phenoxy, 4-chlorophenoxy, 3,4-difluorophenoxy, 4-methoxyphenoxy, 3-methoxy-4-fluorophenoxy, 4-fluorophenoxy, 4-trifluoromethylphenoxy, cyclohexyloxy, phenylsulfanyl, and phenylsulfonyl.

30. A compound as in claim 26 , wherein R 2 is selected from the group consisting of phenoxy, 4-chlorophenoxy, 3,4-difluorophenoxy, 4-methoxyphenoxy, 3-methoxy-4-fluorophenoxy, 4-fluorophenoxy, and 4-trifluoromethylphenoxy.

31. A compound as in claim 26 , wherein R 3 is hydrogen.

32. A compound as in claim 26 , wherein R is selected from hydrogen, methyl, and deuterium.

33. A compound as in claim 32 , wherein R is hydrogen.

34. A compound as in claim 26 , wherein R′ is selected from deuterium, methyl, propyl, isopropyl, hydroxymethyl, carboxymethyl, 4-aminobutyl, imidazol-4-ylmethyl, benzyl, and 4-hydroxybenzyl, or alternatively, R and R′ and the carbon pendent thereto can be joined to form a cyclopropyl.

35. A compound as in claim 34 , wherein R′ is methyl.

36. A compound as in claim 26 , wherein R″ is hydrogen or R″ together with R′ and the nitrogen pendent thereto can be joined to form a pyrrolidinyl.

37. A compound as in claim 26 , wherein R″ is hydrogen.

38. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

39. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

40. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

41. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

42. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

43. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

44. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

45. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

46. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

47. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

48. A compound represented by formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof.

49. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

50. A method for treating a condition mediated at least in part by hypoxia inducible factor (HIF) and/or erythropoietin (EPO), said method comprising administering to a mammalian patient a therapeutically effective amount of a pharmaceutical composition comprising a compound of claim 2 and pharmaceutically acceptable excipient or carrier wherein said condition is selected from the group consisting of anemic disorders, neurological disorders and/or injuries, stroke, trauma, epilepsy, neurodegenerative disease, myocardial infarction, liver ischemia, renal ischemia, peripheral vascular disorders, ulcers, bums, chronic wounds, pulmonary embolism, and ischemic-reperfusion injury.

51. A composition comprising the compound of claim 1 or a mixture of compounds of claim 2 in combination with at least one additional therapeutic agent.

52. The composition of claim 51 wherein the additional therapeutic agent is erythropoietin.